Naples Global Advisors LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 4.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 79,455 shares of the biopharmaceutical company’s stock after purchasing an additional 3,592 shares during the period. Naples Global Advisors LLC’s holdings in Pfizer were worth $2,916,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. NewSquare Capital LLC raised its stake in shares of Pfizer by 0.4% during the 2nd quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock worth $1,976,000 after acquiring an additional 266 shares in the last quarter. Northwest Wealth Management LLC increased its stake in Pfizer by 2.4% during the 3rd quarter. Northwest Wealth Management LLC now owns 11,311 shares of the biopharmaceutical company’s stock valued at $415,000 after purchasing an additional 268 shares in the last quarter. Aevitas Wealth Management Inc. increased its stake in Pfizer by 1.7% during the 2nd quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock valued at $520,000 after purchasing an additional 269 shares in the last quarter. Cutter & CO Brokerage Inc. increased its stake in Pfizer by 2.0% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock valued at $448,000 after purchasing an additional 274 shares in the last quarter. Finally, Beaumont Asset Management L.L.C. increased its stake in Pfizer by 1.3% during the 2nd quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock valued at $694,000 after purchasing an additional 276 shares in the last quarter. 69.08% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE PFE opened at $35.28 on Friday. The company’s fifty day moving average price is $36.74 and its 200 day moving average price is $36.59. Pfizer Inc. has a 1 year low of $27.88 and a 1 year high of $40.97. The company has a market capitalization of $196.05 billion, a PE ratio of 14.00, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $12.13 billion for the quarter, compared to the consensus estimate of $12.30 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The firm’s quarterly revenue was down 4.3% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.84 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 4.31%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
A number of research analysts have issued reports on PFE shares. ValuEngine lowered shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Mizuho restated a “buy” rating and set a $43.00 price target on shares of Pfizer in a research note on Tuesday, September 15th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $37.00 price target on the stock in a research note on Thursday. Morgan Stanley upped their price target on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Finally, SVB Leerink increased their price objective on shares of Pfizer from $42.00 to $43.00 and gave the stock a “market perform” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average target price of $39.66.
In related news, Director Ronald E. Blaylock acquired 13,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the acquisition, the director now directly owns 4,000 shares in the company, valued at approximately $154,200. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Pfizer Inc acquired 1,200,000 shares of the firm’s stock in a transaction on Tuesday, October 27th. The shares were bought at an average cost of $10.00 per share, for a total transaction of $12,000,000.00. Following the completion of the acquisition, the insider now owns 27,349,211 shares of the company’s stock, valued at $273,492,110. The disclosure for this purchase can be found here. Corporate insiders own 0.08% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Are we seeing the beginning of a new bubble?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.